Caroline Hirsch

TL;DR: This is a protocol for a Cochrane Review to assess whether SARS-CoV-2-neutralising mAbs are effective and safe for treating patients with COVID-19 in comparison to an active comparator, placebo or no intervention.

TL;DR: A systematic review of prospective studies published from 10/12/2021 onwards in medical databases to assess clinical efficacy parameters, humoral and cellular immunogenicity and adverse events (AE) following two doses of COVID-19 approved vaccines was conducted in this paper .

TL;DR: This protocol is a protocol for a Cochrane Review (intervention) to assess the effectiveness and safety of SARS-CoV-2-neutralising mAbs, including mAb fragments, and to maintain the currency of the evidence using a living systematic review approach.

TL;DR: The availability of existing literature on immune response and long-term clinical outcomes after COVID-19 vaccination is provided to provide an overview and to map this evidence according to the examined populations, specific vaccines, immunity parameters, and their way of determining relevant long- term outcomes.

TL;DR: In this article , the authors present a protocol for a Cochrane review (intervention) to assess the benefits and adverse effects of vaccines for the prevention of infections in adults with haematological malignancies.